Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nosis-Tcell-001
- Development stage
- Preclinical
- Lead developer
- Nosis Biosciences
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Nosis-Tcell-001 is an experimental RNA-based therapeutic being developed by Nosis Biosciences for the treatment of immunological and inflammatory diseases. The drug utilizes Nosis Bio's proprietary tissue-targeted delivery platform, which is designed to deliver RNA payloads specifically to T cells. As of 2024, the program is in the lead selection stage of preclinical development. The specific molecular target and the exact RNA modality (e.g., siRNA, mRNA, or antisense) have not been publicly disclosed, but the program aims to leverage targeted gene modulation within the immune system to address chronic inflammatory conditions.
Beyond the preview
Go deeper on Nosis-Tcell-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nosis-Tcell-001.